ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0353

Identifying Solutions to Address Racial and Ethnic Health Disparities in Lupus: A Consensus-Based Approach

Joy Buie1, Michael Fisher1, Hannah Tlydsley2, Kristen Backor2 and Karen Costenbader3, 1Lupus Foundation of America, Washington, DC, 2Charles River Associates, San Francisco, CA, 3Brigham and Women's Hospital/ Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2024

Keywords: Access to care, Disparities, Health policy, race/ethnicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Patient Education/Community Programs Poster – ARP

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Health disparities among racial and ethnic minoritized individuals living with lupus remain a critical public health concern. Challenges related to healthcare affordability, accessibility, and quality severely impact health outcomes for these historically marginalized communities. Addressing negative social determinants of health linked to disparate outcomes requires addressing complex challenges including gaps in patient and provider education, absence of financial safety nets, limitations in shared decision-making and lack of access to multidisciplinary care teams. In response, The Lupus Foundation of America, together with an advisory panel of lupus experts, conducted formative research aimed at addressing these complex challenges and ultimately bridging the gap in equity and improving the quality of life for all people living with lupus.

Methods: Curating solutions to address social determinants of health was a stepwise process. Initially, we conducted a literature review of primary sources using PubMed with MeSH/non-MeSH terms according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines. A secondary search of keywords provided a baseline understanding of potential solutions and initiatives underway. An advisory panel of lupus experts iteratively reviewed the list of literature-scoped solutions in working sessions, filling knowledge gaps and classifying solutions based on area of focus, feasibility, and impact. Seven in-depth semi-structured interviews with pharmaceutical industry experts; diversity, equity, and inclusion specialists; and select members of the advisory panel were leveraged to further refine the list of solutions. Finally, a modified Delphi survey approach was leveraged to align the advisory panel based on feasibility, impact, and implementation costs.

Results: Thirty-three solutions were identified and classified into four key categories: Financial Safety Net, Patient Education and Shared Decision-Making, Physician Education, and Other Solutions. Some solutions, such as “Creating resources to help patients and providers locate patient-level financial assistance” and “Programs supporting care-related costs for commercially insured patients,” have several initiatives underway. Other solutions, such as “Guidance on how education can be implemented for various demographics,” do not appear to have ongoing efforts. Overall high-priority solutions identified included “Collecting granular information like patient-reported outcomes to provide personalized care and accelerate development of new products,” “Expanding Medicaid coverage via infrastructure,” and “Supporting people living with lupus in applying and getting approval for disability.”

Conclusion: Addressing health and healthcare disparities linked to negative social determinants of health is a key goal in management of lupus, where disparities in outcomes can be stark. Increasing the visibility of potential solutions and aligning the community on top priorities can enable more efficient and effective contributions to healthcare equity and ultimately better health outcomes for lupus patients.

Supporting image 1


Disclosures: J. Buie: None; M. Fisher: None; H. Tlydsley: None; K. Backor: None; K. Costenbader: Amgen, 2, 5, AstraZeneca, 5, Bain HealthSciences, 2, Bristol-Myers Squibb(BMS), 2, Cabaletta Bio, 2, 5, Exagen, 5, Gilead, 5, Glaxo Smith Kline, 2, 5, Merck, 5.

To cite this abstract in AMA style:

Buie J, Fisher M, Tlydsley H, Backor K, Costenbader K. Identifying Solutions to Address Racial and Ethnic Health Disparities in Lupus: A Consensus-Based Approach [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/identifying-solutions-to-address-racial-and-ethnic-health-disparities-in-lupus-a-consensus-based-approach/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identifying-solutions-to-address-racial-and-ethnic-health-disparities-in-lupus-a-consensus-based-approach/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology